

1081760

RSVP Phantom™ Pelvis, 510(k) Summary

JUL 29 2008

510(k) Owner/Applicant: The Phantom Laboratory, Incorporated  
Joshua R. Levy, President

Mailing Address: P.O. Box 511, Salem, NY 12865

Telephone: (518) 692-1190  
Fax: (518) 692-3329

Date: June 6, 2008

Device Name: Trade Name – RSVP Phantom™ Pelvis  
Classification Name – Accelerator, linear, medical  
(892.5050, Product Code IYE)

Equivalent Device: RSVP Phantom™, 510(k) submission number K954634

Device Description: The RSVP Phantom™ Pelvis provides isodose distribution and verification information for both conventional and intensity modulated radiation therapy machines. The life-size pelvic shape is formed from CAB material and filled with water to simulate the radiation absorption and scatter of human soft tissue.

Intended Use: The RSVP Phantom™ Pelvis is designed for use in a variety of radiation therapy applications including, final quality verification of therapy dose delivery and for comparing the delivered dose profiles for different treatment plans. It is also used for periodic quality assurance evaluations and acceptance testing and to perform reevaluations after equipment or software upgrades.

Technological Comparison: The RSVP Phantom™ Pelvis and the predicate device, RSVP Phantom™, are both designed to evaluate maximum delivered dose to an identified location for radiation therapy machines. Both phantoms are formed from CAB material and filled with water to simulate human tissue, and mimic actual patient absorbed dosages.

Testing Conclusions: During the creation of prototypes for the RSVP Phantom™ Pelvis, as part of the development process, numerous measurements and pressure leak tests were conducted in accordance with the Phantom Laboratory's ISO 9001:2000

## RSVP Phantom™ Pelvis, 510(k) Summary

registered quality system. The measurement equipment used was calibrated with traceability to NIST.

During the development of the RSVP Phantom™ Pelvis, physicist Charles W. Coffey, II, Ph.D. of Vanderbilt University, conducted additional radiation measurements to verify the functions of the phantom compared to the predicate device. The RSVP Phantom™ Pelvis duplicates the functions of the predicate device, however, the anthropomorphic pelvic form is more effective for pelvic studies.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 29 2008

Mr. Joshua R. Levy  
President  
The Phantom Laboratory, Inc.  
PO Box 511  
SALEM NY 12865

Re: K081760  
Trade/Device Name: RSVP Phantom™ Pelvis  
Regulation Number: 21 CFR 892.5050  
Regulation Name: Medical charged-particle radiation therapy  
Regulatory Class: II  
Product Code: IYE  
Dated: June 6, 2008  
Received: June 20, 2008

Dear Mr. Levy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K081760

Device Name: RSVP Phantom™ Pelvis


### Indications For Use:

The RSVP Phantom™ Pelvis is designed for use in a variety of radiation therapy applications including, final quality verification of therapy dose delivery and for comparing the delivered dose profiles for different treatment plans. It is also used for periodic quality assurance evaluations and acceptance testing and to perform reevaluations after equipment or software upgrades.

Prescription Use   X   AND/OR  
801 Subpart D) (21 CFR 801 Subpart C)

Over-The-Counter Use \_\_\_\_\_ (Part 21 CFR

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF  
NEEDED)

  
(Division Sign-Off)  
Division of Reproductive, Abdominal and  
Radiological Devices  
510(k) Number   K081760